Altogether, our studies support the critical role of hepatic ChREBP in triggering insulin-sensitive signals and explore ways to target ChREBP to curb metabolic syndromes linked with insulin resistance like NAFLD and T2DM. The gene discussed is MLXIPL; the disease is metabolic dysfunction-associated steatotic liver disease.